drugset / Trial / NCT00907322

A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults

NCT00907322

Phase 1 Completed 12 enrolled Pfizer Medivation, Inc. · collab
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Dimebon following single ascending doses. A formal single ascending dose study of this nature has not been performed to date in the Dimebon development program.

Timeline

Start
2009-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 20 mg Oral
Subject Latrepirdine Small molecule 40 mg Oral
Subject Latrepirdine Small molecule 60 mg Oral

Indications

No indication recorded.